Compare CMRE & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMRE | COLL |
|---|---|---|
| Founded | 1974 | 2002 |
| Country | Monaco | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | 2010 | 2015 |
| Metric | CMRE | COLL |
|---|---|---|
| Price | $15.94 | $47.29 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $12.00 | ★ $51.17 |
| AVG Volume (30 Days) | 465.6K | ★ 503.6K |
| Earning Date | 02-06-2026 | 02-26-2026 |
| Dividend Yield | ★ 2.90% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.51 | 1.63 |
| Revenue | ★ $2,085,335,000.00 | $757,067,000.00 |
| Revenue This Year | N/A | $26.17 |
| Revenue Next Year | N/A | $3.65 |
| P/E Ratio | ★ $6.34 | $28.92 |
| Revenue Growth | ★ 79.87 | 26.34 |
| 52 Week Low | $6.63 | $23.23 |
| 52 Week High | $16.94 | $50.79 |
| Indicator | CMRE | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 53.36 | 51.33 |
| Support Level | $15.06 | $44.43 |
| Resistance Level | $16.94 | $47.78 |
| Average True Range (ATR) | 0.53 | 2.03 |
| MACD | -0.08 | -0.12 |
| Stochastic Oscillator | 47.34 | 61.18 |
Costamare Inc is an international owner and operator of containerships and dry bulk vessels. The company charter its containerships to the liner companies, providing transportation of containerized cargoes. It charter its dry bulk vessels to a wide variety of customers, providing transportation for dry bulk cargoes. The company's fleet of vessels includes Cosco Guangzhou, Cosco Ningbo, Cosco Yantian, Vantage, Valor, Valiant, Maersk Kobe, and among others. Costamare provides services to ocean carriers that demand a high standard of safety and reliability. It generates a majority of its revenue from the United States of America.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.